ORPHA:100057
Renin-angiotensin-aldosterone system-blocker-induced angioedema
Also known as: ACE inhibitor-related acquired angioedema · ACEI-related acquired angioedema · Acquired angioedema with normal C1 inhibitor · Acquired angioedema with normal C1INH · RAAS-blocker-induced angioedema · RAAS-blocker-induced angioneurotic edema · RAE · Renin-angiotensin-aldosterone system-blocker-induced angioneurotic edema
Publications
10
21.1th percentile
Trials
0
Interventional, condition-specific
Researchers
58
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Renin-angiotensin-aldosterone system (RAAS)-blocker induced angioedema (RAE) is a type of acquired angioedema (AAE) characterized by acute edema in subcutaneous tissues, viscera and/or the upper airway.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015057
- MeSH:C535293
- UMLS:C1304495
Additional Mondo synonyms (5)
Raas-blocker-induced angioedema · Raas-blocker-induced angioneurotic edema · Raas-blocker-induced angioneurotic oedema · renin-angiotensin-aldosterone system-blocker-induced angioneurotic edema · renin-angiotensin-aldosterone system-blocker-induced angioneurotic oedema
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
10 matched papers (5 in last 10 years) Source
- Phenotype characterisedPresent
13 HPO annotations (e.g. Abnormal capillary physiology; Respiratory distress; Erythema) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 148 for broader category angioedema
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
13
Associated phenotypes · MONDO:0015057
- Abnormal capillary physiology
- Respiratory distress
- Erythema
- Pruritus
- Angioedema
Showing 5 of 13 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
10
10 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
10 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
5 in the last 10 years · medium confidence · 21.1th percentile (publications denominator)
Phrase hits: 6 · MeSH hits: 4
Who's working on it?
58
Distinct author names in 10 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Bouillet L2 papers · 2020
National Reference Center for Angioedema (CREAK), Department of Internal Medicine/Clinical Immunology, Grenoble Alpes University Hospital, Grenoble, France.
Papers in Europe PMC - 02Greve J2 papers · 2019
Department for Otorhinolaryngology, Head and Neck Surgery, Ulm University Hospital, Ulm, Germany.
Papers in Europe PMC - 03Hoffmann TK2 papers · 2019
Department for Otorhinolaryngology, Head and Neck Surgery, Ulm University Hospital, Ulm, Germany.
Papers in Europe PMC - 04Aerts JM1 paper · 2010Papers in Europe PMC
- 05Ahmadzadeh S1 paper · 2023
Department of Anesthesiology, Louisiana State University Health Science Center at Shreveport, 1501 Kings Highway, Shreveport, LA, 71103, USA.
Papers in Europe PMC - 06Bas M1 paper · 2010
Hals-, Nasen- und Ohrenklinik, Klinikum rechts der Isar, Technische Universität München, München. basmurat@web.de
Papers in Europe PMC - 07Belbézier A1 paper · 2020
National Reference Center for Angioedema (CREAK), Department of Internal Medicine/Clinical Immunology, Grenoble Alpes University Hospital, Grenoble, France.
Papers in Europe PMC - 08Bier H1 paper · 2010Papers in Europe PMC
- 09Boccon-Gibod I1 paper · 2016Papers in Europe PMC
- 10Bocquet A1 paper · 2020
National Reference Center for Angioedema (CREAK), Department of Internal Medicine/Clinical Immunology, Grenoble Alpes University Hospital, Grenoble, France.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 148 trials are registered for angioedema, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
medium confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
148 interventional trials matched angioedema, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: angioedema
148
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT04334031·RECRUITING·Deployment o the Multidisciplinary Prospective Cohort Imminent
Conditions: Chronic Inflammatory Disease · Angioedema · Severe Asthma · Lupus·Matched via name phrase
- NCT07046806·RECRUITING·Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients
Conditions: Hereditary Angioedema (HAE) · Angioedema · Bradykinin-mediated Angioedema · C1 Inhibitor Deficiency·Matched via name phrase
- NCT07428499·RECRUITING·Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
Conditions: Hereditary Angioedema (HAE) · Hereditary Angioedema - Type 1 · Hereditary Angioedema - Type 2 · HAE·Matched via name phrase
- NCT07204938·ENROLLING BY INVITATION·A Long-Term Study of Navenibart in Participants With Hereditary Angioedema
Conditions: Hereditary Angioedema (HAE)·Matched via name phrase
- NCT04933721·ENROLLING BY INVITATION·Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies
Conditions: Hereditary Angioedema · HAE·Matched via name phrase
- NCT06361537·RECRUITING·Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
Conditions: Acute Hereditary Angio Edema·Matched via name phrase
- NCT07654829·NOT YET RECRUITING·Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)
Conditions: Hereditary Angioedema·Matched via name phrase
- NCT07293364·RECRUITING·A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema
Conditions: Hereditary Angioedema (HAE)·Matched via name phrase
- NCT06818474·RECRUITING·Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
Conditions: Angioedema·Matched via name phrase
- NCT07298447·RECRUITING·Donidalorsen Treatment in Children With Hereditary Angioedema
Conditions: Hereditary Angioedema (HAE)·Matched via name phrase
- NCT06679881·RECRUITING·Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Conditions: Hereditary Angioedema (HAE)·Matched via name phrase
- NCT05396105·ENROLLING BY INVITATION·Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
Conditions: Hereditary Angioedema · Hereditary Angioedema Type I · Hereditary Angioedema Type II · Hereditary Angioedema Types I and II·Matched via name phrase
- NCT07266805·RECRUITING·Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
Conditions: Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)·Matched via name phrase
- NCT06960213·RECRUITING·STOP-HAE: A Phase 3 Study of ADX-324 in HAE
Conditions: Hereditary Angioedema · HAE · Hereditary Angioedema - Type 1 · Hereditary Angioedema - Type 2·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Renin-angiotensin-aldosterone system-blocker-induced angioedema — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Renin-angiotensin-aldosterone system-blocker-induced angioedema" OR "ACE inhibitor-related acquired angioedema" OR "ACEI-related acquired angioedema" OR "Acquired angioedema with normal C1 inhibitor" OR "Acquired angioedema with normal C1INH" OR "RAAS-blocker-induced angioedema" OR "RAAS-blocker-induced angioneurotic edema" OR "Renin-angiotensin-aldosterone system-blocker-induced angioneurotic edema" OR "Raas-blocker-induced angioneurotic oedema" OR "renin-angiotensin-aldosterone system-blocker-induced angioneurotic oedema"
MeSH descriptor terms unioned into the query: Reactive angioendotheliomatosis
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Renin-angiotensin-aldosterone system-blocker-induced angioedema" OR "ACE inhibitor-related acquired angioedema" OR "ACEI-related acquired angioedema" OR "Acquired angioedema with normal C1 inhibitor" OR "Acquired angioedema with normal C1INH" OR "RAAS-blocker-induced angioedema" OR "RAAS-blocker-induced angioneurotic edema" OR "Renin-angiotensin-aldosterone system-blocker-induced angioneurotic edema" OR "Raas-blocker-induced angioneurotic oedema" OR "renin-angiotensin-aldosterone system-blocker-induced angioneurotic oedema" OR "Reactive angioendotheliomatosis"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"angioedema"
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: RAE
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T06:58:55.270Z
